The PHEDRA trial met its primary endpoint, demonstrating that neoadjuvant pyrotinib, trastuzumab, and docetaxel achieved a significantly higher rate of tpCR than placebo, trastuzumab, and docetaxel (41.0% versus 22.0%; absolute difference, 19.0%, one-sided P < 0.0001) in patients with HER2-positive early or locally advanced breast cancer. Here, ERBB2 is linked to breast cancer.